Skip to main content
CAPR
NASDAQ Life Sciences

Capricor Q2 Loss Widens to $40.7M; New HQ Lease and Insider Selling Plans Disclosed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.58
Mkt Cap
$385.114M
52W Low
$2.96
52W High
$40.37
52W Position info
122% above low
Off High info
84% below high
Rel. Volume info
16× avg
Market data snapshot near publication time

CAPR has more than doubled off its 52-week low of $2.96 on elevated volume (16× avg).

Summary

Capricor reported a wider Q2 loss and disclosed a major new headquarters lease, insider selling plans, and new litigation, all while facing an FDA advisory committee's negative vote on its lead drug.


Key Events · Earnings and Guidance · CAPR

  • Q2 Loss Widens to $40.7M

    Net loss increased 57% year-over-year to $40.7M, driven by a 148% jump in G&A expenses to $14.1M as the company ramps pre-commercial activities.

  • Cash Position Declines to $237.9M

    Cash, equivalents, and marketable securities fell from $318.1M at year-end to $237.9M, though management states this funds operations for at least 12 months.

  • New Headquarters Lease Signed

    Capricor entered a lease for 171,001 sq ft in San Diego with $31.6M in tenant improvement allowances and initial monthly base rent of $958K, contingent on FDA approval of deramiocel.

  • Five Directors Adopt 10b5-1 Selling Plans

    Directors adopted trading plans covering up to 442,826 shares, with expiration dates ranging from December 2026 to July 2027.


Analysis · CAPR · Life Sciences

Capricor's Q2 loss widened to $40.7M from $25.9M a year ago, driven by a 148% surge in G&A expenses as the company prepares for potential commercialization of deramiocel. Cash and marketable securities fell to $237.9M from $318.1M at year-end, though management says this funds operations for at least 12 months. The filing also reveals a major new headquarters lease with $31.6M in tenant improvement allowances and five directors adopting 10b5-1 trading plans covering up to 442,826 shares. These disclosures come amid an FDA advisory committee's 9-3 vote against deramiocel's effectiveness for cardiomyopathy and a new patent infringement lawsuit from Mesoblast.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CAPR was trading at $6.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.1M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $8.95 info
Change: +$0.730 (+9%) info
Market Cap: $523.251M info
CAPR
Sep 29, 2026, 9:24 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $10.27
Real-time Price: $8.95 info
Change: -$1.32 (-13%) info
Market Cap: $523.251M info
CAPR
Aug 24, 2026, 9:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.89
Real-time Price: $8.95 info
Change: +$2.06 (+30%) info
Market Cap: $523.251M info
CAPR
Aug 24, 2026, 9:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.89
Real-time Price: $8.95 info
Change: +$2.06 (+30%) info
Market Cap: $523.251M info
CAPR
Aug 21, 2026, 1:47 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $6.12
Real-time Price: $8.95 info
Change: +$2.83 (+46%) info
Market Cap: $523.251M info